Clene Inc., a pioneering biopharmaceutical company specializing in neurological disease research, will present its innovative therapeutic approach at the D. Boral Capital Inaugural Global Conference on May 14, 2025. The event, to be held at The Plaza Hotel in New York City, will provide an opportunity for investors and industry professionals to engage directly with the company's leadership.
President and CEO Rob Etherington will be available for one-on-one meetings throughout the day, offering potential investors and stakeholders an in-depth look at the company's groundbreaking research in neurodegenerative disease treatment. Clene's primary focus is on developing therapies that improve mitochondrial health and protect neuronal function across challenging conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis.
The company's lead investigational therapy, CNM-Au8®, represents a potentially transformative approach to neurological disease management. This first-in-class treatment targets mitochondrial function and the NAD pathway while simultaneously reducing oxidative stress. By improving central nervous system cells' survival and function, CNM-Au8® offers a novel mechanism for addressing complex neurological challenges.
Based in Salt Lake City, Utah, with research and development operations in Maryland, Clene has positioned itself at the forefront of neurological therapeutics research. The upcoming conference presentation provides a critical platform for showcasing the company's scientific advancements and potential therapeutic innovations to a key audience of investors and industry experts.
The conference represents a significant opportunity for Clene to highlight its unique approach to neurological disease treatment, potentially attracting additional research funding, investor interest, and scientific collaboration. By focusing on mitochondrial health and cellular function, the company is pursuing a sophisticated strategy that could yield substantial breakthroughs in understanding and treating previously challenging neurological conditions.
